Several other brokerages have also commented on CBAY. Roth Capital reissued a “buy” rating on shares of CymaBay Therapeutics in a research report on Tuesday, February 19th. Zacks Investment Research lowered CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, January 21st. Leerink Swann started coverage on CymaBay Therapeutics in a research report on Friday, February 22nd. They set an “outperform” rating and a $22.00 price objective for the company. Piper Jaffray Companies set a $30.00 price objective on CymaBay Therapeutics and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, Oppenheimer set a $18.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a report on Sunday, December 9th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $19.38.
CymaBay Therapeutics stock traded up $0.25 on Monday, hitting $12.72. 314,231 shares of the stock traded hands, compared to its average volume of 714,305. The firm has a market capitalization of $739.81 million, a P/E ratio of -10.10 and a beta of 1.84. CymaBay Therapeutics has a 1 year low of $6.31 and a 1 year high of $15.00.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fosun International Ltd increased its holdings in CymaBay Therapeutics by 70.8% in the 4th quarter. Fosun International Ltd now owns 792,096 shares of the biopharmaceutical company’s stock worth $6,199,000 after buying an additional 328,289 shares in the last quarter. Nexthera Capital LP boosted its position in CymaBay Therapeutics by 9.7% in the third quarter. Nexthera Capital LP now owns 908,664 shares of the biopharmaceutical company’s stock worth $10,068,000 after purchasing an additional 80,009 shares during the last quarter. Redmile Group LLC boosted its position in CymaBay Therapeutics by 1.2% in the third quarter. Redmile Group LLC now owns 2,993,565 shares of the biopharmaceutical company’s stock worth $33,169,000 after purchasing an additional 35,800 shares during the last quarter. GSA Capital Partners LLP purchased a new position in CymaBay Therapeutics in the third quarter worth about $693,000. Finally, MetLife Investment Advisors LLC boosted its position in CymaBay Therapeutics by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 43,720 shares of the biopharmaceutical company’s stock worth $484,000 after purchasing an additional 15,542 shares during the last quarter. Institutional investors own 98.00% of the company’s stock.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Read More: What is a Fiduciary?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.